Claims for Patent: 5,225,445

Summary for Patent: 5,225,445

Title:	Phenethanolamine derivatives having .beta..sub.2 -adrenoreceptor selective stimulant action
Abstract:	Phenethanolamine derivatives are disclosed of formula ##STR1## wherein m is 2 to 8; n is 1 to 7 provided that m+n is 4 to 12; Ar is phenyl or phenyl substituted by one or two halogen atoms, alkyl or alkoxy groups or by an alkylenedioxy group; R.sup.1 and R.sup.2 are hydrogen or alkyl provided that the sum total of carbon atoms in R.sup.1 and R.sup.2 is not more than 4; and the physiologically acceptable salts and solvates thereof. The compounds have a selective stimulant action at .beta..sub.2 -adrenoreceptors and may be used inter alia in the treatment of diseases associated with reversible airways obstructions such as asthma and chronic bronchitis. The compounds may be formulated in conventional manner as pharmaceutical compositions with physiologically acceptable carriers or excipients. The compounds may be prepared, for example by alkylation of an amine: ##STR2## where R.sup.3, R.sup.5 and R.sup.6 is hydrogen or a protecting group, followed by removal of any protecting group.
Inventor(s):	Skidmore; Ian F. (Welwyn, GB2), Lunts; Lawrence H. C. (Broxbourne, GB2), Finch; Harry (Hitchin, GB2), Naylor; Alan (Royston, GB2)
Assignee:	Glaxo Group Ltd. (London)
Application Number:	07/837,783
Patent Claims:	1. A method of treating a patient suffering from a disease associated with reversible airways obstruction which comprises administering to the patient an effective amount of a compound of general formula (I) ##STR33## wherein m is an integer from 2 to 8 and n is an integer from 1 to 7 with the proviso that the sum total of m+n is 4 to 12; Ar represents a phenyl group which may be unsubstituted or substituted by one or two substituents selected from halogen atoms, C.sub.1-3 alkyl and C.sub.1-3 alkoxy groups, or by an alkylenedioxy group of formula --O(CH.sub.2).sub.p O-- where p is 1 or 2; and R.sup.1 and R.sup.2, which may be the same or different, each represents a hydrogen atom or a C.sub.1-3 alkyl group with the proviso that the sum total of carbon atoms in R.sup.1 and R.sup.2 is not more than 4; or a physiologically acceptable salt or solvate thereof. 2. A method according to claim 1, wherein m is 3 and n is 6; or m is 4 and n is 3, 4 or 5; or m is 5 and n is 2, 3, 4 or 5; or m is 6 and n is 2 or 3. 3. A method according to claim 1, wherein the sum total of m+n is 7, 8, 9 or 10. 4. A method according to claim 1, wherein R.sup.1 and R.sup.2, which may be the same or different, each represents a hydrogen atom or a methyl group. 5. A method according to claim 1, Ar represents an unsubstituted phenyl group or a phenyl group substituted by one substituent selected from chlorine and fluorine atoms, methoxy and methyl groups. 6. A method according to claim 1, comprising administering an effective amount of a compound of the general formula (Ia): ##STR34## wherein m is an integer from 3 to 6 and n is an integer from 2 to 6 with the proviso that the sum total of m+n is 7 to 10 inclusive; and Ar is phenyl or phenyl substituted by a methyl or methoxy group or a fluorine or chlorine atom; or the physiologically acceptable salts and solvates thereof. 7. A method according to claim 6, wherein R.sup.1 is a hydrogen atom and R.sup.2 is a hydrogen atom or a methyl group. 8. A method according to claim 6, wherein R.sup.1 and R.sup.2, which may be the same or different is each a hydrogen atom or a methyl group, m is 4 or 5, n is 2, 3 or 4 and Ar is phenyl or phenyl substituted by a chlorine or fluorine atom or a methoxy or methyl group. 9. A method according to claim 1, wherein the compound is selected from the group consisting of 4-hydroxy-.alpha..sup.1 -[[[6-(2-phenylethoxy)hexyl]amino]methyl]-1,3-benzenedimethanol; 4-hydroxy-.alpha..sup.1 -[[[5-(4-phenylbutoxy)pentyl]amino]-methyl]-1,3-benzenedimethanol; 4-hydroxy-.alpha..sup.1 -[[[1-methyl-6-(2-phenylethoxy)hexyl]-amino]methyl]-1,3-benzenedimethanol; 4-hydroxy-.alpha..sup.1 -[[[1-methyl-5-(3-phenylpropoxy)pentyl]amino]methyl]-1,3-benzenedimethanol 4-hydroxy-.alpha..sup.1 -[[[1-methyl-5-(4-phenylbutoxy)pentyl]amino]methyl]-1,3-benzenedimethanol; 4-hydroxy-.alpha..sup.1 -[[[1-ethyl-6-(2-phenylethoxy)hexyl]-amino]methyl]-1,3-benzenedimethanol; .alpha..sup.1 -[[[1,1-dimethyl-6-(2-phenylethoxy)hexyl]amino]-methyl-4-hydroxy-1,3-benze nedimethanol; .alpha..sup.1 -[[[6-[2-(4-fluorophenyl)ethoxy]-1-methylhexyl]-amino]methyl]-4-hydroxy-1, 3-benzenedimethanol; 4-hydroxy-.alpha..sup.1 -[[[6-[3-(4-methoxyphenyl)propoxy]-1methylhexyl]amino]methyl]-1,3-benzened imethanol; 4-hydroxy-.alpha..sup.1 -[[[1-methyl-6-(4-phenylbutoxy)hexyl]amino]methyl]-1,3-benzenedimethanol; 4-hydroxy-.alpha..sup.1 -[[[6-[2-(4-methylphenyl)ethoxy]hexyl]amino]methyl]-1,3-benzenedimethanol; .alpha..sup.1 -[[[6-[2-(3-chlorophenyl)ethoxy]hexyl]amino]methyl]-4-hydroxy-1,3-benzened imethanol; 4-hydroxy-.alpha..sup.1 -[[[6-[2-(4-methoxyphenyl)ethoxy]hexyl]amino]-methyl]-1,3-benzenedimethano l; .alpha..sup.1 -[[[6-[3-(4-fluorophenyl)propoxy]hexyl]amino]-methyl]-4-hydroxy-1,3-benzen edimethanol; or the physiologically acceptable salts thereof. 10. A method according to claim 1, wherein the disease is asthma or chronic bronchitis. 11. A method of treating a patient suffering from an inflammatory or allergic skin disease, or a condition in which there is an advantage in lowering gastric acidity which method comprises administering to the patient an effective amount of a compound of general formula (I) ##STR35## wherein m is an integer from 2 to 8 and n is an integer from 1 to 7 with the proviso that the sum total of m+n is 4 to 12; Ar represents a phenyl group which may be unsubstituted or substituted by one or two substituents selected from halogen atoms, C.sub.1-3 alkyl and C.sub.1-3 alkoxy groups, or by an alkylenedioxy group of formula --O(CH.sub.2).sub.p O-- where p is 1 or 2; and R.sup.1 and R.sup.2, which may be the same or different, each represents a hydrogen atom or a C.sub.1-3 alkyl group with the proviso that the sum total of carbon atoms in R.sup.1 and R.sup.2 is not more than 4; or a physiologically acceptable salt or solvate thereof. 12. A method according to claim 11, wherein m is 3 and n is 6; or m is 4 and n is 3, 4 or 5; or m is 5 and n is 2, 3, 4 or 5; or m is 6 and n is 2 or 3. 13. A method according to claim 11, wherein the sum total of m+n is 7, 8, 9 or 10. 14. A method according to claim 11, wherein R.sup.1 and R.sup.1, which may be the same or different, each represents a hydrogen atom or a methyl group. 15. A method according to claim 11, wherein Ar represents an unsubstituted phenyl group or a phenyl group substituted by one substituent selected from chlorine and fluorine atoms, methoxy and methyl groups. 16. A method according to claim 11, comprising administering a compound of the general formula (Ia): ##STR36## wherein m is an integer from 3 to 6 and n is an integer from 2 to 6 with the proviso that the sum total of m+n is 7 to 10 inclusive; and Ar is phenyl or phenyl substituted by a methyl or methoxy group or a fluorine or chlorine atom; or the physiologically acceptable salts and solvates thereof. 17. A method according to claim 16, wherein R.sup.1 is a hydrogen atom and R.sup.2 is a hydrogen atom or a methyl group. 18. A method according to claim 16, wherein R.sup.1 and R.sup.2, which may be the same or different is each a hydrogen atom or a methyl group, m is 4 or 5, n is 2, 3 or 4 and Ar is phenyl or phenyl substituted by a chlorine or fluorine atom or a methoxy or methyl group. 19. A method according to claim 11, wherein the compound is selected from the group consisting of 4-hydroxy-.alpha..sup.1 -[[[6-(2-phenylethoxy)hexyl]amino]methyl]-1,3-benzenedimethanol; 4-hydroxy-.alpha..sup.1 -[[[5-(4-phenylbutoxy)pentyl]amino]-methyl]-1,3-benzenedimethanol; 4-hydroxy-.alpha..sup.1 -[[[1-methyl-6-(2-phenylethoxy)hexyl]-amino]methyl]-1,3-benzenedimethanol; 4-hydroxy-.alpha..sup.1 -[[[1-methyl-5-(3-phenylpropoxy)pentyl]amino]methyl]-1,3-benzenedimethanol ; 4-hydroxy-.alpha..sup.1 -[[[1-methyl-5-(4-phenylbutoxy)pentyl]amino]methyl]-1,3-benzenedimethanol; 4-hydroxy-.alpha..sup.1 -[[[1-ethyl-6-(2-phenylethoxy)hexyl]amino]methyl]-1,3-benzenedimethanol; .alpha..sup.1 -[[[1,1-dimethyl-6-(2-phenylethoxy)hexyl]amino]-methyl-4-hydroxy-1,3-benze nedimethanol; .alpha..sup.1 -[[[6-[2-(4-fluorophenyl)ethoxy]-1-methylhexyl]amino]methyl]-4-hydroxy-1,3 -benzenedimethanol; 4-hydroxy-.alpha..sup.1 -[[[6-[3-(4-methoxyphenyl)propoxy]-1-methyl hexyl]amino]methyl]-1,3-benzenedimethanol; 4-hydroxy-.alpha..sup.1 -[[[1-methyl-6-(4-phenylbutoxy)hexyl]amino]methyl]-1,3-benzenedimethanol; 4-hydroxy-.alpha..sup.1 -[[[6-[2-(4-methylphenyl)ethoxy]hexyl]amino]methyl]-1,3-benzenedimethanol; .alpha..sup.1 -[[[6-[2-(3-chlorophenyl)ethoxy]hexyl]amino]methyl]-4-hydroxy-1,3-benzened imethanol; 4-hydroxy-.alpha..sup.1 -[[[6-[2-(4-methoxyphenyl)ethoxy]hexyl]amino]-methyl]-1,3-benzenedimethano l; .alpha..sup.1 -[[[6-[3-(4-fluorophenyl)propoxy]hexyl]amino]-methyl]-4-hydroxy-1,3-benzen edimethanol; or the physiologically acceptable salts thereof. 20. A method according to claim 11, wherein the patient is suffering from gastric or peptic ulceration. 21. A method according to claim 11, wherein the patient treated is suffering from psoriasis.